New transplant approach aims to control severe immune and blood disorders

NCT ID NCT04528355

Recruiting now Disease control Sponsor: Paul Szabolcs Source: ClinicalTrials.gov ↗

First seen Jan 13, 2026 · Last updated May 20, 2026 · Updated 14 times

Summary

This study tracks children and adults with non-cancerous blood or immune disorders who receive a stem cell transplant using a milder chemotherapy regimen. The goal is to see how well the transplant works and to monitor side effects like graft-versus-host disease. Up to 50 participants aged 2 months to 60 years will be followed through medical records.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CONGENITAL BONE MARROW FAILURE SYNDROMES are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

UPMC Children's Hospital of Pittsburgh
RECRUITING

Pittsburgh, Pennsylvania, 15224, United States

Contact

Contact

Contact

Contact

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

CONGENITAL BONE MARROW FAILURE SYNDROMES HEREDITARY ANEMIAS INFLAMMATORY CONDITIONS INHERITED METABOLIC DISORDERS (IMD) PRIMARY IMMUNODEFICIENCY (PID)